Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders.

Aviceda Therapeutics is a biotech company developing next-generation immunomodulators for ophthalmic conditions using its proprietary HALOS™ nanotechnology platform.

Maze Therapeutics is a biopharmaceutical company focused on developing precision medicines for renal and metabolic diseases using human genetics.

Adcendo is a biotech company focused on developing antibody-drug conjugates for treating cancers with high unmet needs.

858 Therapeutics is a biotechnology company developing small molecule therapeutics for oncology and immunology, with a lead asset, ETX-19477, in Phase 1 trials for advanced solid tumors.

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.